IBEX 35
11.327,70 +28,40 (+0,25%) Euro Stoxx 50
5.064,14 -8,31 (-0,16%) Dólar/Euro
1,0872 +0,0002 (+0,02%) Petróleo Brent
83,96 +0,69 (+0,83%) Oro
2.419,80 +34,30 (+1,44%) Bitcoin EUR
61.663,43 +19,83 (+0,03%)
Arecor Therapeutics plc (AREC.L)
Arecor Therapeutics plc
Chesterford Research Park
Little Chesterford CB10 1XL
United Kingdom
44 1223 426 060
https://arecor.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Sarah Jennifer Howell Ph.D. | CEO & Director | 421k | 51,46k | 1975 |
| Ms. Susan Day Lowther FCMA | CFO, Company Secretary & Director | 306k | 154,38k | 1960 |
| Dr. Jan Jezek Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Mr. David Gerring | Senior Vice President of Development | N/A | N/A | N/A |
| Dr. Manjit Rahelu Ph.D. | Chief Business Officer | N/A | N/A | N/A |
Descripción
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel, high concentration, thermostable insulin for use by Medtronic's Diabetes business in a next-generation implantable pump. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Arecor Therapeutics plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
